Karen Miller, MD
Pulmonary Disease · Meridian, IDNPI 1629117619
Payments from drug & device makers
Across 184 payments — averaging $6507.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Hoffmann-la Roche Limited$698K
- AstraZeneca$231K
- Astrazeneca UK Limited$142K
- Genentech, Inc.$59K
- Pfizer$55K
- Vertex$10K
- plus $1K from 19 others
Across 1 payment — averaging $1173.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Hoffmann-la Roche Limited | 39 | $698,348 |
| AstraZeneca | 13 | $231,214 |
| Astrazeneca UK Limited | 4 | $141,937 |
| Genentech, Inc. | 24 | $59,265 |
| Pfizer | 5 | $55,407 |
| Vertex | 35 | $9,786 |
| Insmed, Inc. | 8 | $277 |
| AbbVie(2 entities) | 13 | $259 |
| Gilead | 7 | $156 |
| Chiesi USA, Inc. | 5 | $84 |
| Nestle Healthcare Nutrition Inc. | 5 | $75 |
| Advanced Respiratory, Inc | 3 | $68 |
| Eli Lilly | 1 | $66 |
| Mylan Specialty L.p. | 3 | $61 |
| Merck | 4 | $48 |
| Digestive Care, Inc. | 2 | $48 |
| Actelion Pharmaceuticals US, Inc. | 2 | $45 |
| Boehringer Ingelheim | 2 | $40 |
| Baxter Healthcare | 2 | $32 |
| Sunovion Pharmaceuticals Inc. | 2 | $30 |
| Philips North America LLC | 1 | $23 |
| PARI Respiratory Equipment, Inc. | 1 | $23 |
| Shire North American Group Inc | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| United Therapeutics Corporation | 1 | $18 |
How this compares
$1,197,347 in reported general payments places this provider in the 95th percentile of 57 pulmonary disease providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Meridian
- Oleg KouskovMeridian$8K
- Eric ScholtenMeridian$6K
- Matthew DivietroMeridian$4K
- Andrew RegerMeridian$677
- William BergquistMeridian$479
- William DittrichMeridian$310
- David FonsecaMeridian$287
- Olga FortenkoMeridian$190
- Brian GoltryMeridian$151
- David WylerMeridian$73
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.